Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
BACKGROUND & AIMS:Availability of directly-acting antivirals (DAAs) has changed the treatment landscape of hepatitis C virus (HCV) infection. The high price of DAAs has restricted their use in several countries. However, in some countries such as India, generic DAAs are available at much cheaper...
Main Authors: | Rakesh Aggarwal, Qiushi Chen, Amit Goel, Nicole Seguy, Razia Pendse, Turgay Ayer, Jagpreet Chhatwal |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5435174?pdf=render |
Similar Items
-
Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study
by: Xiaojie Wang, et al.
Published: (2019-06-01) -
Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018-04-01) -
Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals
by: Bader Faiyaz Zuberi
Published: (2017-08-01) -
High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C
by: Mai Abozeid, et al.
Published: (2018-10-01) -
High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)